Opus Genetics (IRD) Total Liabilities (2010 - 2026)
Opus Genetics (IRD) reported Total Liabilities of $87.9 million for Q1 2026, up 262.41% year-over-year from $24.3 million in Q1 2025, and up 151.86% on a QoQ basis from $34.9 million in Q4 2025.
Opus Genetics (IRD) has 17 years of Total Liabilities data on file, last reported at $87.9 million in Q1 2026.
- Quarterly Total Liabilities rose 262.41% year-over-year to $87.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $87.9 million (up 262.41% YoY) and the FY2025 annual result came in at $34.9 million, up 208.94% from the prior year.
- Total Liabilities climbed to $87.9 million in Q1 2026 per IRD's latest filing, from $34.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $87.9 million in Q1 2026 and bottomed at $2.7 million in Q3 2022.
- The 5-year median for Total Liabilities is $5.8 million (2023), against an average of $15.0 million.
- The widest annual swing landed in 2022, when Total Liabilities declined 28.59%; it then surged 404.81% in 2025.
- Tracing IRD's Total Liabilities over 5 years: stood at $2.8 million in 2022, then soared by 46.82% to $4.0 million in 2023, then soared by 179.44% to $11.3 million in 2024, then soared by 208.94% to $34.9 million in 2025, then soared by 151.86% to $87.9 million in 2026.
- Per Business Quant, the three latest IRD Total Liabilities figures stand at $87.9 million (Q1 2026), $34.9 million (Q4 2025), and $30.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | 87.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.89 Mn |
| Dec 31, 2025 | 34.90 Mn |
| Sep 30, 2025 | 30.16 Mn |
| Jun 30, 2025 | 21.19 Mn |
| Mar 31, 2025 | 24.25 Mn |
| Dec 31, 2024 | 11.30 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | 4.20 Mn |
| Mar 31, 2024 | 5.79 Mn |
| Dec 31, 2023 | 4.04 Mn |
| Sep 30, 2023 | 3.91 Mn |
| Jun 30, 2023 | 5.76 Mn |
| Mar 31, 2023 | 4.15 Mn |
| Dec 31, 2022 | 2.75 Mn |
| Sep 30, 2022 | 2.69 Mn |
| Jun 30, 2022 | 3.30 Mn |
| Mar 31, 2022 | 3.21 Mn |
| Dec 31, 2021 | 3.86 Mn |
| Sep 30, 2021 | 2.64 Mn |
| Jun 30, 2021 | 2.70 Mn |
| Mar 31, 2021 | 2.31 Mn |
| Dec 31, 2020 | 31.15 Mn |
| Sep 30, 2020 | 3.12 Mn |
| Jun 30, 2020 | 3.25 Mn |
| Mar 31, 2020 | 2.11 Mn |
| Dec 31, 2019 | 9.34 Mn |
| Sep 30, 2019 | 3.23 Mn |
| Jun 30, 2019 | 4.05 Mn |
| Mar 31, 2019 | 3.49 Mn |
| Dec 31, 2018 | 5.48 Mn |
| Sep 30, 2018 | 7.46 Mn |
| Jun 30, 2018 | 6.81 Mn |
| Mar 31, 2018 | 7.58 Mn |
| Dec 31, 2017 | 11.52 Mn |
| Sep 30, 2017 | 9.47 Mn |
| Jun 30, 2017 | 12.19 Mn |
| Mar 31, 2017 | 18.45 Mn |
| Dec 31, 2016 | 3.99 Mn |
| Sep 30, 2016 | 5.50 Mn |
| Jun 30, 2016 | 4.72 Mn |
| Mar 31, 2016 | 8.35 Mn |
| Dec 31, 2015 | 6.03 Mn |
| Sep 30, 2015 | 5.37 Mn |
| Jun 30, 2015 | 5.94 Mn |
| Mar 31, 2015 | 7.10 Mn |
| Dec 31, 2014 | 6.95 Mn |
| Sep 30, 2014 | 7.86 Mn |
| Jun 30, 2014 | 8.94 Mn |
| Mar 31, 2014 | 13.09 Mn |
| Dec 31, 2013 | 6.93 Mn |
| Sep 30, 2013 | 6.22 Mn |
| Jun 30, 2013 | 5.57 Mn |
| Mar 31, 2013 | 4.98 Mn |
| Dec 31, 2012 | 5.39 Mn |
| Sep 30, 2012 | 3.24 Mn |
| Jun 30, 2012 | 2.09 Mn |
| Mar 31, 2012 | 3.05 Mn |
| Dec 31, 2011 | 2.98 Mn |
| Sep 30, 2011 | 8.52 Mn |
| Jun 30, 2011 | 10.40 Mn |
| Dec 31, 2010 | 5.82 Mn |